Friday, 16 October 2026European Markets

ENDÚR Stock Bullish By 33% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of ENDÚR (Oslo Børs Benchmark Index_GI: ENDUR.OL) jumped by a staggering 33.82% in 21 sessions from kr32.5 to kr43.49 at 16:26 EST on Tuesday, after three consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is rising 1% to kr1,176.93, following the last session's upward trend.

About ENDÚR

Endúr ASA operates as a supplier of construction and maintenance projects, services, and solutions for marine infrastructure businesses in Norway and internationally. It operates through Marine infrastructure, Aquaculture Solutions, and Other segments. The company engages in the construction and maintenance of facilities for land-based aquaculture, quays, harbors, dams, bridges, and other specialized concrete and steel projects. It also offers maritime and ship maintenance services. In addition, the company produces concrete barges for the aquaculture industry. The company was formerly known as Bergen Group ASA and changed its name to Endúr ASA in February 2019. Endúr ASA was founded in 2007 and is headquartered in Bergen, Norway.

Earnings Per Share

As for profitability, ENDÚR has a trailing twelve months EPS of kr-1.62.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ENDÚR's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for ENDÚR is 34640 which is 86.91% below its average volume of 166939.

More news about ENDÚR (ENDUR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com